

Innovations in staging of prostate cancer

Poster Session 66

Monday, 27 March
12:15 - 13:45

Location: Room London, North Hall (Level 1)

Chairs: N. Fossati, Milan (IT)
M. Lardas, Nea Smirni-Athens (GR)
J. Hugosson, Göteborg (SE)

Aims and objectives of this session

This session will examine Innovations in prostate cancer staging, prognostic groups and lymph node identification.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

869

11C-choline versus 68Ga-PSMA PET/CT scan for the detection of nodal recurrence from prostate cancer: Results from a large, multi-institutional salvage lymph node dissection series

By: Fossati N.¹, Briganti A.¹, Gandaglia G.¹, Suardi N.¹, Colicchia M.², Karnes J.², Haidl F.³, Porres D.³, Pfister D.³, Heidenreich A.³, Herlemann A.⁴, Gratzke C.⁴, Stief C.⁴, Battaglia A.⁵, Everaerts W.⁵, Joniau S.⁵, Van Poppel H.⁵, Aksenov A.⁶, Osmonov D.K.⁶, Jünemann K.P.⁶, Abreu A.D.L.⁸, Almeida F.⁸, Fay C.⁷, Gill I.⁷, Mottrie A.M.⁹, Montorsi F.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, ³University of Cologne, Dept. of Urology, Cologne, Germany, ⁴Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ⁵University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, ⁶University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, ⁷Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern Cal, USC Institute of Urology, Los Angeles, California, United States of America, ⁸Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, ⁹OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium

870

Introducing PSMA-Bone-PET-Index for quantitative assessment of osseous tumor burden in prostate cancer

By: Bieth M.², Krönke M.², Maurer T.¹, Tauber R.¹, Dahlbender M.¹, Retz M.¹, Gschwend J.¹, Nekolla S.², Menze B.², Eiber M.², Schwaiger M.²

Institutes:¹Klinikum rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, ²Klinikum rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany

871

Performance of 111In-PSMA-ligand radioguided surgery for identification of lymph node metastases: Correlation of tracer uptake and histopathology based on 310 single lymph nodes separated from lymphadenectomies in prostate cancer patients

By: Schaal K.¹, Mix M.², Stoykow C.², Bartholomä M.², Drendel V.³, Mäcke H.², Gourni E.², Wetterauer U.¹, Schultze-Seemann W.¹, Meyer P.T.², Jilg C.A.¹

Institutes:¹Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Urology, Freiburg, Germany, ²Medical Center, University of Freiburg, Faculty of Medicine, Dept. of Nuclear Medicine, Freiburg, Germany, ³Medical Center, University of Freiburg, Faculty of Medicine, Institute for Pathology, Freiburg, Germany

872

Prospective comparison of molecular and histopathologic detection of lymph node metastases in prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection: Prediction of biochemical recurrence

By: Heck M.¹, Retz M.¹, Bandur M.¹, Souchay M.¹, Vitzthum E.¹, Weirich G.², Schuster T.³, Autenrieth M.¹, Kübler H.¹, Maurer T.¹, Thalgott M.¹, Herkommer K.¹, Gschwend J.¹, Nawroth R.¹

Institutes:¹Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Urology, Munich, Germany, ²Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Pathology, Munich, Germany, ³McGill University, Dept. of Family Medicine, Montreal, Canada

873